Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SAGE

Sage Therapeutics Inc

Dec 20 • 04:00PM ET

5.61

Dollar change +0.61
Percentage change 12.20	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB REGN AMGN VRTX LLY NBIX GILD ACAD MRNA INCY

| Held by: VTI XBI IWM VXF VB IWN VBK IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-5.58	Insider Own	11.92%	Shs Outstand	61.17M	Perf Week	4.18%
Market Cap	385.05M	Forward P/E	-	EPS next Y	-3.76	Insider Trans	0.00%	Shs Float	53.88M	Perf Month	14.26%
Income	-337.59M	PEG	-	EPS next Q	-1.52	Inst Own	85.29%	Short Float	12.11%	Perf Quarter	-22.41%
Sales	106.40M	P/S	3.62	EPS this Y	28.22%	Inst Trans	-4.24%	Short Ratio	7.89	Perf Half Y	-51.47%
Book/sh	9.02	P/B	0.62	EPS next Y	42.08%	ROA	-42.95%	Short Interest	6.53M	Perf Year	-73.13%
Cash/sh	8.31	P/C	0.67	EPS next 5Y	16.80%	ROE	-49.34%	52W Range	4.62 - 28.26	Perf YTD	-74.11%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-2.28%	ROI	-60.07%	52W High	-80.15%	Beta	0.93
Dividend TTM	-	Quick Ratio	10.02	Sales past 5Y	3395.58%	Gross Margin	91.75%	52W Low	21.43%	ATR (14)	0.40
Dividend Ex-Date	-	Current Ratio	10.02	EPS Y/Y TTM	49.20%	Oper. Margin	-349.50%	RSI (14)	50.27	Volatility	8.34% 6.99%
Employees	487	Debt/Eq	0.02	Sales Y/Y TTM	837.52%	Profit Margin	-317.29%	Recom	2.84	Target Price	8.94
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	54.52%	Payout	-	Rel Volume	5.24	Prev Close	5.00
Sales Surprise	9.93%	EPS Surprise	0.80%	Sales Q/Q	337.08%	Earnings	Oct 29 AMC	Avg Volume	827.04K	Price	5.61
SMA20	2.21%	SMA50	-7.92%	SMA200	-45.21%	Trades		Volume	4,336,741	Change	12.20%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-21-24	Upgrade	RBC Capital Mkts	Underperform → Sector Perform	$4
Oct-10-24	Resumed	Raymond James	Mkt Perform
Oct-04-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$10 → $4
Jul-30-24	Downgrade	TD Cowen	Buy → Hold	$16 → $10
Jul-25-24	Downgrade	JP Morgan	Overweight → Neutral	$18 → $12
May-29-24	Initiated	Robert W. Baird	Neutral	$15
May-29-24	Initiated	Citigroup	Sell	$8
Apr-17-24	Downgrade	BofA Securities	Neutral → Underperform	$24 → $14
Dec-12-23	Initiated	Deutsche Bank	Hold	$21
Aug-08-23	Downgrade	Needham	Buy → Hold
Aug-08-23	Downgrade	Goldman	Buy → Neutral	$22
Aug-08-23	Downgrade	Canaccord Genuity	Buy → Hold	$64 → $21
Aug-07-23	Downgrade	Wedbush	Outperform → Neutral	$51 → $22
Aug-07-23	Downgrade	Stifel	Buy → Hold	$60 → $22
Aug-07-23	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$71 → $25
Aug-07-23	Downgrade	Oppenheimer	Outperform → Perform
Aug-07-23	Downgrade	BofA Securities	Buy → Neutral	$66 → $25
Jul-27-23	Initiated	Scotiabank	Sector Outperform
Mar-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$40 → $60
Jan-03-23	Downgrade	Guggenheim	Buy → Neutral

Show Previous Ratings

Dec-17-24 07:20AM	Sage Therapeutics price target lowered to $6 from $10 at Stifel (TipRanks)
Nov-26-24 07:00AM	Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +9.09%
Nov-22-24 06:40AM	Sage Therapeutics price target lowered to $4 from $7 at BofA (TipRanks) +6.60%
Nov-21-24 11:56AM	Sage ends dalzanemdor development following Phase II trial failure (Clinical Trials Arena)
Nov-20-24 10:36AM	After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder (Benzinga)
06:41AM	Loading…
06:41AM	Sages string of research failures continues (BioPharma Dive)
06:30AM	Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease (Business Wire)
Oct-31-24 07:39AM	Sage Therapeutics price target lowered to $26 from $52 at Piper Sandler (TipRanks) -5.59%
Oct-30-24 07:38AM	Biogen, Sage admit a defeat in major depression (BioPharma Dive) -24.06%
03:13AM	Sage Therapeutics Inc (SAGE) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Oct-29-24 05:20PM	Sage Therapeutics, Inc. (SAGE) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates (Business Wire)
Oct-28-24 10:10AM	Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE (PR Newswire) +6.62%
Oct-23-24 10:00AM	Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE (PR Newswire)
05:45AM	Sage Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE (PR Newswire)
10:01AM	Loading…
Oct-22-24 10:01AM	Sage Therapeutics, Inc. (SAGE) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-18-24 03:02PM	State Street Corp's Strategic Acquisition of Sage Therapeutics Shares (GuruFocus.com)
Oct-17-24 03:56PM	Sage lays off 55% of R&D workforce and refocuses pipeline (Pharmaceutical Technology)
12:32PM	Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline (GuruFocus.com)
10:16AM	Sage Therapeutics CFO, GC, CTO to depart in wide restructuring plan (CFO Dive)
10:11AM	After Series Of Trial Setbacks, Sage Therapeutics To Lay Off One-Third Workforce (Benzinga)
09:47AM	Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard. (Barrons.com)
08:08AM	Sage to cut one-third of workforce, streamline drug pipeline (BioPharma Dive)
07:00AM	Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE Commercialization and Focus its Development Portfolio (Business Wire)
Oct-15-24 06:30AM	Sage Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 (Business Wire)
Oct-10-24 08:46AM	Sage Therapeutics price target lowered to $8 from $9 at Wedbush (TipRanks)
Oct-08-24 10:53AM	Sage Therapeutics Reports Disappointing Study Results for Alzheimers Treatment (Barrons.com)
09:19AM	After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study (Benzinga)
08:52AM	Talkiatry Expands Postpartum Depression Care Services to Close Gaps in Maternal Mental Healthcare (PR Newswire)
08:21AM	Sage continues downslide as Alzheimers study fails (BioPharma Dive)
07:36AM	Loading…
07:36AM	Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimers Treatment (Barrons.com)
07:06AM	Sage Therapeutics stock drops after disappointing Alzheimer's trial results (Investing.com)
06:30AM	Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimers Disease (Business Wire)
Oct-04-24 09:14AM	Sage stock slides as RBC cuts rating to Sell on trial results concerns (Investing.com) -5.01%
Sep-29-24 07:54AM	Sage Therapeutics, Inc. (SAGE): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-27-24 07:28AM	SAGE Therapeutics SAGE-324 Collaboration with Biogen Ends (TipRanks)
Sep-26-24 10:37AM	Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate (Benzinga)
07:00AM	Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program (Business Wire)
Sep-25-24 11:34AM	Sage Therapeutics, Inc. (SAGE) Hits 52-Week Lows After Trial Failures, According to Short Sellers (Insider Monkey)
Sep-24-24 05:45AM	Shareholders of Sage Therapeutics, Inc. Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE (PR Newswire)
Sep-10-24 05:45AM	Sage Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SAGE (PR Newswire)
Sep-05-24 08:30AM	Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE (PR Newswire)
Aug-30-24 11:31AM	Sage Therapeutics (SAGE) Down 17.1% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-08-24 10:00AM	Sage Therapeutics Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SAGE (PR Newswire)
Aug-01-24 11:27AM	Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise (Zacks) -10.87%
Jul-31-24 05:20PM	Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Sage Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Pipeline and Business Progress (Business Wire)
Jul-25-24 04:52AM	Sage and Biogens SAGE-324 shows no benefit in essential tremor trial (Clinical Trials Arena)
Jul-24-24 04:07PM	Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails (Investor's Business Daily) -20.64%
10:34AM	Sage Therapeutics Stock Slides as Pipeline Thins (Barrons.com)
10:01AM	Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
08:10AM	Biogen, Sage tremor drug fails key trial (BioPharma Dive)
06:30AM	Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor (Business Wire)
Jul-22-24 01:12AM	Sage Therapeutics/Biogens episodic therapy zuranolone could change MDD treatment (Clinical Trials Arena)
Jul-17-24 06:30AM	Sage Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, July 31, 2024 (Business Wire)
Jun-11-24 06:30AM	Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntingtons Disease (Business Wire)
Jun-05-24 06:30AM	Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-29-24 12:12PM	Baird predicts steady growth for SAGE Therapeutics at $15 target (Investing.com) -8.97%
09:52AM	American downgraded, United upgraded: Wall Street's top analyst calls (The Fly)
May-13-24 07:57PM	15 Most Depressed States in the US (Insider Monkey)
May-07-24 06:30AM	Sage Therapeutics to Participate in Upcoming May Investor Conferences (Business Wire)
Apr-30-24 12:57PM	Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-26-24 11:27AM	Sage Therapeutics (SAGE) Q1 Earnings Miss, Sales Beat Estimates (Zacks)
Apr-25-24 02:33PM	Truist Securities Cuts Sage Therapeutics' Price Target to $18 From $22, Hold Rating Maintained (MT Newswires)
10:54AM	SAGE Stock Earnings: Sage Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:04AM	Sage Therapeutics Inc (SAGE) Q1 2024 Earnings: Mixed Results Amidst Pipeline Progress (GuruFocus.com)
07:35AM	Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress (Business Wire)
Apr-18-24 11:37AM	Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal (Zacks)
10:01AM	Sage Therapeutics, Inc. (SAGE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-17-24 04:10PM	Sage Stock Collapses To Record Low After Parkinson's Drug Misses Its Mark (Investor's Business Daily) -19.58%
02:41PM	Neurodegenerative Disorder-Focused Sage Therapeutics Stock Falls On Disappointing Parkinson's Data (Benzinga)
08:46AM	Sage Therapeutics Hammered After Parkinson's Drug Misses The Mark (Investor's Business Daily)
07:44AM	Sages cognition drug fails in Parkinsons study (BioPharma Dive)
06:39AM	Sage Therapeutics' Parkinson's drug fails in mid-stage study (Reuters)
06:30AM	Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson's Disease (Business Wire)
Apr-11-24 07:29PM	12 Best All-Time Low Stocks To Invest In (Insider Monkey) -6.82%
06:30AM	Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024 (Business Wire)
Apr-10-24 06:09PM	12 Best Depressed Stocks To Buy in 2024 (Insider Monkey)
07:47AM	New postpartum depression drugs are here. Diagnosis, treatment hurdles still stand in the way. (BioPharma Dive)
Mar-18-24 10:16AM	25 Most Stressed Cities in the United States (Insider Monkey)
Mar-15-24 11:30AM	Why Is Sage Therapeutics, Inc. (SAGE) Down 22% Since Last Earnings Report? (Zacks)
Feb-28-24 06:30AM	Sage Therapeutics to Present at Upcoming March Investor Conferences (Business Wire)
Feb-15-24 01:36PM	Sage Therapeutics (SAGE) Q4 Earnings & Revenues Beat Estimates (Zacks)
10:50AM	Sage Therapeutics, Inc. (NASDAQ:SAGE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-14-24 07:15AM	Sage Therapeutics Inc (SAGE) Reports Fourth Quarter and Full Year 2023 Financial Results (GuruFocus.com) +11.86%
06:42AM	Sage offers details on launch of new postpartum depression pill (BioPharma Dive)
06:30AM	Sage Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Highlights Pipeline and Business Progress (Business Wire)
Feb-07-24 10:00AM	Will Sage Therapeutics, Inc. (SAGE) Report Negative Earnings Next Week? What You Should Know (Zacks)
Jan-31-24 06:30AM	Sage Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 14, 2024 (Business Wire)
Jan-08-24 06:32AM	Sage Therapeutics to Provide Business Updates at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +16.91%
06:30AM	Sage Therapeutics Announces Changes to Board of Directors (Business Wire)
Jan-02-24 06:30AM	Sage Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 (Business Wire)
Dec-20-23 02:15PM	11 Most Promising Psychedelic Stocks According to Hedge Funds (Insider Monkey) -6.03%
Dec-14-23 06:30AM	ZURZUVAE (zuranolone) CIV, a Landmark Oral Treatment for Women with Postpartum Depression (PPD), is Now Available in the U.S. (Business Wire)
Dec-07-23 11:31AM	Why Is Sage Therapeutics, Inc. (SAGE) Up 12.7% Since Last Earnings Report? (Zacks)
Nov-13-23 11:13AM	Sage Therapeutics, Inc. (NASDAQ:SAGE) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 01:11PM	Sage Therapeutics (SAGE) Q3 Earnings Lag Estimates, Down 5% (Zacks) -5.76%
07:59AM	Biogens Earnings Top Estimates. Wall Street Still Has Questions About Growth. (Barrons.com)
06:30AM	Sage Therapeutics to Present at Upcoming November Investor Conferences (Business Wire)

SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. It focuses on diseases and disorders of the brain. Its products include ZURZUVAE and ZULRESSO. The company was founded by Steven Marc Paul and Douglas Covey on April 16, 2010 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JONAS JEFFREY M	Officer	Dec 10 '24	Proposed Sale	5.53	7,500	41,441		Dec 13 08:47 PM
IGUCHI KIMI	CFO & Treasurer	Jan 02 '24	Option Exercise	1.36	1,642	2,233	70,429	Jan 04 04:07 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SAGE

Sage Therapeutics Inc

Upgrade your FINVIZ experience